BioMarin Pharmaceutical Inc. BMRN
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- -2.15%
- 1 year
- +8.55%
- Open
- 58.66
- Prev close
- 58.51
- Mkt cap
- 11.26B
- Vol
- 366.32K
- Avg vol
- 2.25M
- EPS
- 0.37
- P/E
- 157.16
- Div yield
- 0.00%
More statistics
- Low
- 58.08
- High
- 59.50
- Forward P/E
- 9.12
- Beta
- 0.21
- Short ratio
- 5.25
- Inst. own
- 103.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 60.80
- 200-d avg
- 58.42
- 1y target
- 91.56
News
2 days ago defenseworld.net
BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and…
-
4 days ago benzinga.com
BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
4 days ago prnewswire.com
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront…
1 week ago prnewswire.com
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
1 week ago defenseworld.net
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN
Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to its most recent filing with the SEC. The fund bought…
-
1 week ago benzinga.com
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
-
1 week ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
2 weeks ago zacks.com
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 weeks ago defenseworld.net
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F…
-
2 weeks ago benzinga.com
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.
2 weeks ago zacks.com
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 weeks ago defenseworld.net
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
-
3 weeks ago benzinga.com
BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth
The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-blind, placebo-controlled trial evaluating the effect of VOXZOGO on the growth of the foramen magnum…
3 weeks ago prnewswire.com
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026…
3 weeks ago zacks.com
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
3 weeks ago prnewswire.com
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/…
1 month ago cnbc.com
BioMarin reports five-year Pompe disease data showing durable motor function
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no…
-
1 month ago benzinga.com
BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease…
1 month ago prnewswire.com
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN)…
1 month ago businesswire.com
Profluent Partners With BioMarin to Design Novel Medicines Using AI
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme…
1 month ago defenseworld.net
Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two…
1 month ago seekingalpha.com
BioMarin: Why I See Significant Upside Into 2027
Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1…
1 month ago marketbeat.com
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth…
1 month ago zacks.com
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
-
1 month ago benzinga.com
BioMarin Pharmaceutical Decides To Discontinue Development Of VOXZOGO For Children With Noonan Syndrome
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after…
1 month ago seekingalpha.com
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago prnewswire.com
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
1 month ago benzinga.com
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.
-
2 months ago benzinga.com
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105
Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.
2 months ago benzinga.com
Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20.…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $59 to $60.
2 months ago benzinga.com
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
2 months ago benzinga.com
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.
-
2 months ago benzinga.com
Reported Earlier, BioMarin Settles Global Yuviwel Dispute, Secures Up To 20% Sales Royalty
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including…
2 months ago benzinga.com
This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
2 months ago benzinga.com
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98
BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.
2 months ago benzinga.com
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $59
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $60 to $59.
-
2 months ago benzinga.com
BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.…
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.
-
2 months ago benzinga.com
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $105 to $111.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114
Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $111 to $114.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $119 to $124.
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $95 to $97.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.
-
2 months ago benzinga.com
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est
BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to…
-
2 months ago benzinga.com
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over…